This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Medicaid & Government Pricing Congress
May 16-18, 2023
The Omni Shoreham HotelWashington, DC

Tom Moore
Vice President, US Market Access, Marketing, Contracting & Trade at Amgen


Tom Moore is the Vice President of US Market Access, Marketing, Contracting and Trade for Amgen, Inc. He reports to the head of the US Commercial Business Organization, Ian Thompson. In this role Mr. Moore is responsible for coordinating and leading Amgen’s effort to secure quality patient access across all payer types for its innovative and biosimilar medicines.

Mr. Moore has held numerous US and international commercial leadership roles at Amgen, including government affairs, brand access, patient services, value marketing and national payer accounts. Prior to his current role Mr. Moore led Market Access for Canada and emerging markets in Latin America, Turkey, Middle East, and Africa. Mr. Moore has also led Amgen’s coordinated biosimilar strategies for its European business and served as the chair of EuropaBio’s biosimilars working group.

Prior to joining Amgen Mr. Moore gained extensive government affairs and federal reimbursement experience in Washington, DC. He began his professional career as a Congressional aide, where he specialized on matters relating to international policy, trade, and health care. After departing public service Mr. Moore concentrated on helping improving US patient access to health with the US pharmaceutical trade association, PhRMA.

Mr. Moore is graduate of Virginia Commonwealth University. As an undergraduate student Mr. Moore served as an enlisted soldier (Infantry) in the U.S. Army National Guard.

Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.

Agenda Sessions

  • Opening Keynote: Analysis and Perspective on the Current State of Drug Policy and Pricing